How Schizophrenia Develops: Cognitive and Brain Mechanisms Underlying Onset of Psychosis

Trends in Cognitive Sciences

Volumn 19, Issue 12, 2015, Pages 744-756

  Cannon, Tyrone D ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN; SCAFFOLDS;

BRAIN CONNECTIVITY; NEURAL MECHANISMS; PHYSIOLOGICAL MARKERS; PREDICTION ERRORS; PREFRONTAL CORTEX; SOURCE ATTRIBUTION; SYNAPTIC PLASTICITY; TRIGGERING MECHANISM;

DISEASES;

DOPAMINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

BRAIN FUNCTION; COGNITION; DENDRITIC SPINE; EGO; EPISODIC MEMORY; EXCITATION; GRAY MATTER; HALLUCINATION; HIGH RISK PATIENT; HUMAN; INHIBITION (PSYCHOLOGY); MEDIAL PREFRONTAL CORTEX; MICROGLIA; NERVE CELL DIFFERENTIATION; NERVE CELL PLASTICITY; PATHOPHYSIOLOGY; PRODROMAL SYMPTOM; PYRAMIDAL NERVE CELL; REVIEW; SCHIZOPHRENIA; SYNAPSE; BRAIN; PATHOLOGY; PHYSIOLOGY; PSYCHOSIS;

BRAIN; COGNITION; HUMANS; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 84950271491     PISSN: 13646613     EISSN: 1879307X     Source Type: Journal    
DOI: 10.1016/j.tics.2015.09.009     Document Type: Review

References (104)

1. Johnson M.K. Memory and reality. Am. Psychol. 2006, 61:760-771.
2. Stephan K.E., et al. Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring. Schizophr. Bull. 2009, 35:509-527.
3. Glausier J.R., Lewis D.A. Dendritic spine pathology in schizophrenia. Neuroscience 2013, 251:90-107.
4. Fusar-Poli P., et al. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch. Gen. Psychiatry 2012, 69:220-229.
5. Cannon T.D., et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch. Gen. Psychiatry 2008, 65:28-37.
6. Fatemi S.H., Folsom T.D. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr. Bull. 2009, 35:528-548.
7. Gonzalez-Burgos G., Lewis D.A. NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia. Schizophr. Bull. 2012, 38:950-957.
8. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III - the final common pathway. Schizophr. Bull. 2009, 35:549-562.
9. Karlsgodt K.H., et al. Structural and functional brain abnormalities in schizophrenia. Curr. Dir. Psychol. Sci. 2010, 19:226-231.
10. Karlsgodt K.H., et al. The neurodevelopmental hypothesis of schizophrenia. Schizophrenia: The Final Frontier 2011, 3-18. Psychology Press. A.S. David (Ed.).
11. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry 1987, 44:660-669.
12. Feinberg I. Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence?. J. Psychiatr. Res. 1982, 17:319-334.
13. McGlashan T.H., Hoffman R.E. Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Arch. Gen. Psychiatry 2000, 57:637-648.
14. Wellman C.L. Dendritic reorganization in pyramidal neurons in medial prefrontal cortex after chronic corticosterone administration. J. Neurobiol. 2001, 49:245-253.
15. Walker E., et al. Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia. Annu. Rev. Clin. Psychol. 2008, 4:189-216.
16. Cannon T.D., et al. Early and late neurodevelopmental influences in the prodrome to schizophrenia: contributions of genes, environment, and their interactions. Schizophr. Bull. 2003, 29:653-669.
17. Borgwardt S.J., et al. Reductions in frontal, temporal and parietal volume associated with the onset of psychosis. Schizophr. Res. 2008, 106:108-114.
18. Pantelis C., et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 2003, 361:281-288.
19. Sun D., et al. Progressive brain structural changes mapped as psychosis develops in 'at risk' individuals. Schizophr. Res. 2009, 108:85-92.
20. Takahashi T., et al. Progressive gray matter reduction of the superior temporal gyrus during transition to psychosis. Arch. Gen. Psychiatry 2009, 66:366-376.
21. Ziermans T.B., et al. Progressive structural brain changes during development of psychosis. Schizophr. Bull. 2012, 38:519-530.
22. Cannon T.D., et al. Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk. Biol. Psychiatry 2015, 77:147-157.
23. Takahashi T., et al. Insular cortex gray matter changes in individuals at ultra-high-risk of developing psychosis. Schizophr. Res. 2009, 111:94-102.
24. Walter A., et al. Hippocampal volume in subjects at high risk of psychosis: a longitudinal MRI study. Schizophr. Res. 2012, 142:217-222.
25. Dorph-Petersen K.A., et al. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology 2005, 30:1649-1661.
26. Fusar-Poli P., et al. Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neurosci. Biobehav. Rev. 2013, 37:1680-1691.
27. Ho B.C., et al. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch. Gen. Psychiatry 2011, 68:128-137.
28. Navari S., Dazzan P. Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychol. Med. 2009, 39:1763-1777.
29. Frick L.R., et al. Microglial dysregulation in psychiatric disease. Clin. Dev. Immunol. 2013, 2013:608654.
30. Monji A., et al. Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatry Clin. Neurosci. 2009, 63:257-265.
31. Rao J.S., et al. Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in the postmortem frontal cortex from schizophrenia patients. Schizophr. Res. 2013, 147:24-31.
32. Milner R., Campbell I.L. The extracellular matrix and cytokines regulate microglial integrin expression and activation. J. Immunol. 2003, 170:3850-3858.
33. Walker F.R., et al. Dynamic structural remodelling of microglia in health and disease: a review of the models, the signals and the mechanisms. Brain Behav. Immun. 2014, 37:1-14.
34. Doorduin J., et al. Neuroinflammation in schizophrenia-related psychosis: a PET study. J. Nucl. Med. 2009, 50:1801-1807.
35. 11C]PK11195 positron emission tomography study. Biol. Psychiatry 2008, 64:820-822.
36. 18F]-FEPPA. Schizophr. Bull. 2015, 41:85-93.
37. Brandt V.C., et al. Did I turn off the gas? Reality monitoring of everyday actions. Cogn. Affect. Behav. Neurosci. 2014, 14:209-219.
38. Buda M., et al. A specific brain structural basis for individual differences in reality monitoring. J. Neurosci. 2011, 31:14308-14313.
39. Simons J.S., et al. Separable forms of reality monitoring supported by anterior prefrontal cortex. J. Cogn. Neurosci. 2008, 20:447-457.
40. Sugimori E., et al. Brain mechanisms underlying reality monitoring for heard and imagined words. Psychol. Sci. 2014, 25:403-413.
41. Haut K.M., et al. Contributions of feature binding during encoding and functional connectivity of the medial temporal lobe structures to episodic memory deficits across the prodromal and first-episode phases of schizophrenia. Clin. Psychol. Sci. 2015, 3:159-174.
42. Ragland J.D., et al. Neural correlates of relational and item-specific encoding during working and long-term memory in schizophrenia. Neuroimage 2012, 59:1719-1726.
43. Ranganath C., et al. The cognitive neuroscience of memory function and dysfunction in schizophrenia. Biol. Psychiatry 2008, 64:18-25.
44. van Erp T.G., et al. Remember and know judgments during recognition in chronic schizophrenia. Schizophr. Res. 2008, 100:181-190.
45. Fusar-Poli P., et al. Cognitive functioning in prodromal psychosis: a meta-analysis. Arch. Gen. Psychiatry 2012, 69:562-571.
46. Giuliano A.J., et al. Neurocognition in the psychosis risk syndrome: a quantitative and qualitative review. Curr. Pharm. Des. 2012, 18:399-415.
47. Chung Y., et al. Prodromal symptom severity predicts accelerated gray matter reduction and third ventricle expansion among clinically high risk youth developing psychotic disorders. Mol. Neuropsychiatry 2015, 1:13-22.
48. Marshall C., et al. The content of attenuated psychotic symptoms in those at clinical high risk for psychosis. Psychiatry Res. 2014, 219:506-512.
49. Allen P.P., et al. Misattribution of external speech in patients with hallucinations and delusions. Schizophr. Res. 2004, 69:277-287.
50. Woodward T.S., Menon M. Misattribution models (II): source monitoring in hallucinating schizophrenia subjects. The Neuroscience of Hallucinations 2013, 169-184. Springer. R. Jardi (Ed.).
51. Galimberti D., et al. Psychiatric symptoms in frontotemporal dementia: epidemiology, phenotypes, and differential diagnosis. Biol. Psychiatry 2015, Published online April 7, 2015. 10.1016/j.biopsych.2015.03.028.
52. Barch D.M., Sheffield J.M. Cognitive impairments in psychotic disorders: common mechanisms and measurement. World Psychiatry 2014, 13:224-232.
53. Sun D., et al. Elucidating a magnetic resonance imaging-based neuroanatomic biomarker for psychosis: classification analysis using probabilistic brain atlas and machine learning algorithms. Biol. Psychiatry 2009, 66:1055-1060.
54. Dandash O., et al. Altered striatal functional connectivity in subjects with an at-risk mental state for psychosis. Schizophr. Bull. 2014, 40:904-913.
55. Heinze K., et al. Discrete alternations of brain network structural covariance in individuals at ultra-high risk for psychosis. Biol. Psychiatry 2015, 77:989-996.
56. Lord L.D., et al. Characterization of the anterior cingulate's role in the at-risk mental state using graph theory. Neuroimage 2011, 56:1531-1539.
57. Wotruba D., et al. Aberrant coupling within and across the default mode, task-positive, and salience network in subjects at risk for psychosis. Schizophr. Bull. 2014, 40:1095-1104.
58. Anticevic A., et al. Association of thalamic dysconnectivity and conversion to psychosis in youth and young adults at elevated clinical risk. JAMA Psychiatry 2015, 72:882-891.
59. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 1991, 148:1301-1308.
60. Krystal J.H., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 1994, 51:199-214.
61. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 1995, 52:998-1007.
62. Lahti A.C., et al. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 2001, 25:455-467.
63. Lewis D.A., Sweet R.A. Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies. J. Clin. Invest. 2009, 119:706-716.
64. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014, 511:421-427. Schizophrenia Working Group of the Psychiatric Genomics Consortium.
65. Dempster K., et al. Glutamatergic metabolite correlations with neuropsychological tests in first episode schizophrenia. Psychiatry Res. 2015, 233:180-185.
66. Stone J.M., et al. Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Biol. Psychiatry 2009, 66:533-539.
67. Lutkenhoff E.S., et al. Proton MRS in twin pairs discordant for schizophrenia. Mol. Psychiatry 2010, 15:308-318.
68. Umbricht D., Krljes S. Mismatch negativity in schizophrenia: a meta-analysis. Schizophr. Res. 2005, 76:1-23.
69. Bodatsch M., et al. Prediction of psychosis by mismatch negativity. Biol. Psychiatry 2011, 69:959-966.
70. Javitt D.C., et al. Role of cortical N-methyl-d-aspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:11962-11967.
71. Feldman D.E. Synaptic mechanisms for plasticity in neocortex. Annu. Rev. Neurosci. 2009, 32:33-55.
72. Tessier C.R., Broadie K. Activity-dependent modulation of neural circuit synaptic connectivity. Front. Mol. Neurosci. 2009, 2:8.
73. Schafer D.P., et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 2012, 74:691-705.
74. Corlett P.R., et al. Disrupted prediction-error signal in psychosis: evidence for an associative account of delusions. Brain 2007, 130:2387-2400.
75. Corlett P.R., et al. Ketamine effects on memory reconsolidation favor a learning model of delusions. PLoS ONE 2013, 8:e65088.
76. Howes O.D., et al. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr. Pharm. Des. 2009, 15:2550-2559.
77. Abi-Dargham A., et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am. J. Psychiatry 1998, 155:761-767.
78. Howes O.D., et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch. Gen. Psychiatry 2009, 66:13-20.
79. Egerton A., et al. Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort. Biol. Psychiatry 2013, 74:106-112.
80. Howes O., et al. Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. Mol. Psychiatry 2011, 16:885-886.
81. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am. J. Psychiatry 2003, 160:13-23.
82. Roiser J.P., et al. Neural and behavioral correlates of aberrant salience in individuals at risk for psychosis. Schizophr. Bull. 2013, 39:1328-1336.
83. Tandon R., et al. Schizophrenia 'just the facts' 5. Treatment and prevention. Past, present, and future. Schizophr. Res. 2010, 122:1-23.
84. McGorry P.D., et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch. Gen. Psychiatry 2002, 59:921-928.
85. McGlashan T.H., et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am. J. Psychiatry 2006, 163:790-799.
86. Jentsch J.D., et al. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science 1997, 277:953-955.
87. Javitt D.C. Glutamate and schizophrenia: phencyclidine N-methyl-d-aspartate receptors, and dopamine-glutamate interactions. Int. Rev. Neurobiol. 2007, 78:69-108.
88. Kegeles L.S., et al. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol. Psychiatry 2000, 48:627-640.
89. Insel T.R., Scolnick E.M. Cure therapeutics and strategic prevention: raising the bar for mental health research. Mol. Psychiatry 2006, 11:11-17.
90. Finkel D., et al. Latent growth curve analyses of accelerating decline in cognitive abilities in late adulthood. Dev. Psychol. 2003, 39:535-550.
91. McArdle J.J., et al. Structural modeling of dynamic changes in memory and brain structure using longitudinal data from the normative aging study. J. Gerontol. B: Psychol. Sci. Soc. Sci. 2004, 59:P294-P304.
92. Kumsta R., et al. I.X. Risk causation, mediation, and moderation. Monogr. Soc. Res. Child Dev. 2010, 75:187-211.
93. Yung A.R., McGorry P.D. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr. Bull. 1996, 22:353-370.
94. Beiser M., et al. Establishing the onset of psychotic illness. Am. J. Psychiatry 1993, 150:1349-1354.
95. Yung A.R., et al. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust. N. Z. J. Psychiatry 2005, 39:964-971.
96. Miller T.J., et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr. Bull. 2003, 29:703-715.
97. Wiltink S., et al. Declining transition rates to psychosis: the contribution of potential changes in referral pathways to an ultra-high-risk service. Early Interv. Psychiatry 2015, 9:200-206.
98. Addington J., et al. At clinical high risk for psychosis: outcome for non-converters. Am. J. Psychiatry 2011, 168:800-805.
99. Schlosser D.A., et al. Recovery from an at-risk state: clinical and functional outcomes of putatively prodromal youth who do not develop psychosis. Schizophr. Bull. 2012, 38:1225-1233.
100. Kahn, R.S. et al. Schizophrenia. Nat. Rev. Dis. Primers (in press).
101. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460:748-752. The International Schizophrenia Consortium.
102. Cannon T.D.D What is the role of theories in the study of schizophrenia?. Schizophr. Bull. 2009, 35:563-567.
103. Insel T.R.D Rethinking schizophrenia. Nature 2010, 468:187-193.
104. Kim I.H., et al. Spine pruning drives antipsychotic-sensitive locomotion via circuit control of striatal dopamine. Nat. Neurosci. 2015, 18:883-891.